Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions

Renal Impairment

Interventions

DRUG

NKTR118 Group1

Oral dose, 25 mg

DRUG

NKTR118 Group 2

Oral dose, 25 mg

DRUG

NKTR118 Group3

Oral dose, 25 mg

DRUG

NKTR118

Oral dose, 25 mg

Trial Locations (3)

Research Site, Anaheim

Research Site, Orlando

Research Site, Overland Park